Compare iPierian vs ReproCELL
Customers evaluate the quality of iPierian's products using the following success metrics.
Overview
iPierian is 17 yrs old and is based in United States.
iPierian develops therapies to treat neurodegenerative diseases. The company discovers monoclonal antibodies against targets of the Tau protein for the treatment of Alzheimer's disease and other tauopathies such as progressive supranuclear palsy, and frontotemporal dementia. It was founded in 2007 and is based in South San Francisco, California. In April 2014, iPierian was acquired by Bristol Myers Squibb.
ReproCELL is 21 yrs old and is based in Japan.
ReproCell is a developer of stem cell technologies. The company develops various products, with an underlying theme that focuses on stem cell technology, to address the needs of researchers and clinicians. The product range encompasses reagents for ES/iPS cells and stem cell-derived functional cells.
Demo Video
Leadership
Nancy E. Stagliano (Chief Executive Officer)
Elaine Ferguson (Chief Financial Officer)
Investors
Bristol Myers Squibb, MPM Capital
Mitsubishi UFJ Capital
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because iPierian has not claimed their profile.
Work for iPierian? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for iPierian?
Claim your profile now.
Information not available because ReproCELL has not claimed their profile.
Work for ReproCELL? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for ReproCELL?
Claim your profile now.